Medical devices firm Sensus Healthcare Q3 revenue beats estimates on higher FDA treatment volumes

Reuters11-07
Medical devices firm <a href="https://laohu8.com/S/SRTSW">Sensus Healthcare</a> Q3 revenue beats estimates on higher FDA treatment volumes

Overview

  • Sensus Healthcare Q3 2025 revenue of $6.9 mln beats analyst expectations

  • Net loss for Q3 2025 was $0.9 mln, reflecting operational challenges

  • Adjusted EBITDA for Q3 2025 missed analyst estimates

Outlook

  • Company sees strong interest internationally following MDSAP certification

  • CMS coding expected to strengthen SRT adoption and reimbursement certainty

Result Drivers

  • INCREASED TREATMENT VOLUME - FDA treatment volumes rose 20% over the second quarter, reflecting growing adoption

  • INTERNATIONAL EXPANSION - Shipped 16 SRT systems, including three to China, and preparing for broader expansion

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$6.88 mln

$6.25 mln (5 Analysts)

Q3 Net Income

-$943,000

Q3 Adjusted EBITDA

Miss

-$2.40 mln

-$485,000 (2 Analysts)

Q3 Basic EPS

-$0.06

Q3 Operating Expenses

$5.28 mln

Q3 Pretax Profit

-$2.41 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Sensus Healthcare Inc is $8.00, about 53.9% above its November 5 closing price of $3.69

  • The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw4Cy8Dqa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment